CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
2014 · Clinical Cancer Research · 341 citations
https://doi.org/10.1158/1078-0432.ccr-14-2258
D
Daniel F. Heitjan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
338
Papers
21.3K
Citations
70
h-index
183
i10-index
Daniel F. Heitjan is an academic researcher from Southern Methodist University. The author has contributed to research in topics: Statistical Methods in Clinical Trials & Statistical Methods and Bayesian Inference & Advanced Causal Inference Techniques. The author has an h-index of 70, co-authored 288 publications.
ORCID: 0000-0002-1527-4472Papers by this author
worksUse of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study
2002 · Journal of Clinical Oncology · 156 citations
https://doi.org/10.1200/jco.2002.08.062
Comparison between the analgesic efficacy of transversus abdominis plane (TAP) block and placebo in open retropubic radical prostatectomy: a prospective, randomized, double-blinded study
2013 · Journal of Clinical Anesthesia · 71 citations
https://doi.org/10.1016/j.jclinane.2013.04.009
Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin
2018 · Scientific Reports · 12 citations
https://doi.org/10.1038/s41598-018-33019-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat